NEW YORK CITY, NY / ACCESS Newswire / November 9, 2026 / VCYT shareholders are absorbing losses after Veracyte (NASDAQ:VCYT) lowered the top of its full-year 2026 revenue guidance to $593 million from $596 million on November 4, 2026. The new ceiling sits below a cited analyst estimate of $593.9 million, and the shares fell as the market reacted to a weaker outlook for the Company's Decipher Prostate test. If you lost money on Veracyte stock, you have the right to have those losses evaluated at no cost to you. Shareholders who suffered losses are encouraged to request a free review of their VCYT losses. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
On February 25, 2026, CEO Marc Stapley said the Company remained "extremely confident" in Decipher's "ability to sustain strong double-digit growth in 2026 and beyond." On July 30, 2026, he said "Decipher is on this very straight line," when it comes to growth trajectory, and guided for an additional 20,000, plus or minus 1,000 tests per year.
On November 4, 2026, the Company reported that "Decipher Prostate volume was below our expectations." Veracyte cut Decipher Prostate annual volume increase to just 12,000 to 15,000 tests, a sharp 25-40% cut in annual growth.
The investigation concerns potential securities law violations related to Veracyte's statements about Decipher's 2026 growth. Investors who have already sold their VCYT shares may still be eligible, and there is no upfront cost to have your losses reviewed.
If you purchased Veracyte shares and lost money, submit your VCYT loss details today or call (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the VCYT Investigation
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Veracyte's statements about the growth outlook for its Decipher Prostate test were accurate and complete. The stock price declined after the Company disclosed on November 4, 2026 that Decipher Prostate volume was below its expectations.
Q: When did Veracyte allegedly mislead investors? A: The investigation concerns statements made before the November 4, 2026 disclosure that allegedly caused investors to purchase securities at inflated prices.
Q: Who is eligible to participate in the VCYT investigation? A: Investors who purchased VCYT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do VCYT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my VCYT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought VCYT and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire